Meridian Bioscience Inc (NASDAQ:VIVO)
| 26.00 BATS BZX Real-Time Price As of 12:21pm ET |  +0.02 / +0.08%Today’s Change | 17.00 Today|||52-Week Range 28.72 | +27.45% Year-to-Date |
| SECTOR Health Technology | INDUSTRY Biotechnology | MARKET CAP $1.1B |
Company Description
Meridian Bioscience, Inc. engages in the development, production, sale, and distribution of diagnostic products. Its platforms include molecular, immunoassay, urea breath, and blood chemistry. It operates through the Diagnostics and Life Science segments. The Diagnostics segment consists of manufacturing operations for infectious disease and blood chemistry products and the sale and distribution of diagnostics products domestically and abroad. The Life Science segment distributes bulk antigens, antibodies, polymerase chain reaction/ quantitative PCR reagents, nucleotides, competent cells, and bioresearch reagents used by researchers, agri-bio companies, and other diagnostic manufacturing companies. The company was founded by William J. Motto in 1976 and is headquartered in Cincinnati, OH.
Contact Information
Meridian Bioscience, Inc. 3471 River Hills Drive Cincinnati Ohio 45244 |
Employees
Shareholders
| Mutual fund holders | 55.18% |
| Individual stakeholders | 5.75% |
| Other institutional | 44.74% |
Top Executives
| John Patrick Kenny | Chief Executive Officer & Executive Director |
| Andrew S. Kitzmiller | Chief Financial Officer & Executive Vice President |
| Julie Smith | Chief Accounting Officer, Senior VP & Controller |
| Lourdes Weltzien | Executive Vice President-Life Science |
| Tony Serafini-Lamanna | Executive Vice President-Diagnostics |
